US EditionMultiple Sclerosis and Breast Cancer, New Ema Approvals
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of five medicinal products at its meeting in April 2026. Thus, it has been agreed to grant a marketing authorisation for Cenrifki (tolebrutinib), for the treatment of secondary progressive, non-recurring multiple sclerosis, a disease of the brain and spinal cord in which inflammation destroys the protective layer surround…
The European Medicines Agency recommended, at the end of the meeting of the Committee for Medicinal Products for Human Use (CHMP) on 20-23 April 2026, the approval of five new medicinal products and the extension of the therapeutic indications of nine other medicinal products already authorised in the European Union. Two questions were withdrawn. Among the main innovations is Cenrifki (tolebrutinib), recommended for the treatment of non-relapsin…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
